Details

1. Normal Anatomy and Histology <p>2. Inflammatory and Infectious Conditions</p> <p>3. Urothelial Metaplasia and Hyperplasia</p> <p>4. Polys and Other Non-Neoplastic Benign Conditions</p> <p>5. Benign Epithelial Tumors</p> <p>6. Flat Urothelial Lesions with Atypia and Urothelial Dysplasia</p> <p>7. Urothelial Carcinoma in Situ</p> <p>8. Bladder Cancer: General Features</p> <p>9. Grading of Bladder Cancer</p> <p>10. State pT1 Urothelial Carcinoma</p> <p>11. Staging of Bladder Cancer</p> <p>12. Histologic Variants of Urothelial Carcinoma</p> <p>13. Adenocarcinoma and Its Putative Precursors and Variants</p> <p>14. Squamous Cell Carcinoma and Other Squamous Lesions</p> <p>15. Neuroendocrine Tumors</p> <p>16. Sarcomatoid Carcinoma (Carcinosarcoma)</p> <p>17. Bladder Tumors with Inverted Growth</p> <p>18. Congenital Disorders and Pediatric Pathology</p> <p>19. Soft Tissue Tumors</p> <p>20. Lymphoid and Hematopoeitic Tumors</p> <p>21. Urothelial Carcinoma Following Augmentation Cystoplasty</p> <p>22. Other Rare Tumors</p> <p>23. Secondary Tumors</p> <p>24. Treatment Effects</p> <p>25. Handling and Reporting of Bladder Specimens</p> <p>26. Diagnostic Immunohistochemistry</p> <p>27. Pathology of the Urachus</p> <p>28. Pathology of Renal Pelvis, Ureter, and Urethra</p> <p>29. Molecular Determinants of Tumor Recurrence</p> <p>30. Urinary Cytology</p> <p>31. Evaluation of Hematuria and Urianalysis</p> <p>32. Urine Based Biomarkers</p> <p>33. Tissue Based Biomarkers</p> <p>34. Molecular Pathology of Bladder Cancer.</p>

<p><strong>Liang Cheng</strong>, MD, PhD,?is Professor of Pathology and Urology, Chief of the Genitourinary Pathology Division, and Director of Molecular Diagnostics Service and Molecular Pathology Laboratory in the Department of Pathology and Laboratory Medicine at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Cheng has several best-selling books to his name, as well as over 200 peer-reviewed original research articles. <p><strong>Antonio Lopez-Beltran</strong>, MD, is Professor of Anatomic Pathology in the Departments of Anatomic Pathology and Surgery at Cordoba University School of Medicine in Cordoba, Spain. Among Dr. Lopez-Beltran's many honors and publishing accomplishments, he co-wrote "The 2004 WHO Classification of Bladder Tumors: A Summary and Commentary," which set the current international standard for classifying and staging bladder tumors. <p><strong>David G. Bostwick</strong>, MD, MBA, is Past President of the International Society of Urological Pathology, and several years ago left academic medicine to found his highly successful laboratory medicine company, Bostwick Laboratories, of which he is Chief Medical Officer and President. Dr. Bostwick, based in Richmond, Virginia, is one of the top names in urologic pathology, with several best-selling text- and reference books to his credit.

<p>The human urinary bladder is subject to a unique and extraordinarily diverse array of congenital, inflammatory, metaplastic, and neoplastic abnormalities. This book provides contemporary, comprehensive, and evidence-based practice information for pathologists, urologists, oncologists, and other medical professionals.</p> <p>In <i>Bladder Pathology</i>, a full spectrum of pathologic conditions that afflict the bladder and urothelium are described and lavishly illustrated. With its emphasis on diagnostic criteria and differential diagnoses, this book is of particular value to practicing pathologists—assisting in the pathologist's recognition, understanding, and accurate interpretation of the light microscopic findings in bladder specimens.</p> <p>Features and benefits of this new volume include:</p> <ul> <li> <p>1,741 high-quality color illustrations and 112 tables to illustrate the wide range of pathologic and clinical features of the urinary tract</p> </li> <li> <p>An evidence-based approach to diagnosis and patient management for infectious, nonneoplastic, and neoplastic conditions</p> </li> <li> <p>Recent advances in the molecular genetics of the urinary bladder with discussion of its current or potential impact on diagnosis and personalized patient care</p> </li> <li> <p>Emphasis on the scientific validation of current diagnostic methods and their direct application in clinical practice</p> </li> </ul> <p><i>Bladder Pathology</i> is a cutting-edge resource that not only offers comprehensive research and clinical information for practicing surgical pathologists, urologists, oncologists, and their clinical colleagues, but also captures a genuine sense of excitement about recent advances in this vital, ever-evolving field.</p> <p>Chapters:</p> <ul> <li> <p>Normal Anatomy and Histology</p> </li> <li> <p>Inflammatory and Infectious Conditions</p> </li> <li> <p>Urothelial Metaplasia and Hyperplasia</p> </li> <li> <p>Polyps and Other Nonneoplastic Benign Conditions</p> </li> <li> <p>Benign Epithelial Tumors</p> </li> <li> <p>Flat Urothelial Lesions with Atypia and Urothelial Dysplasia</p> </li> <li> <p>Urothelial Carcinoma in Situ</p> </li> <li> <p>Bladder Cancer: General Features</p> </li> <li> <p>Grading of Bladder Cancer</p> </li> <li> <p>Stage pT1 Urothelial Carcinoma</p> </li> <li> <p>Staging of Bladder Cancer</p> </li> <li> <p>Histologic Variants of Urothelial Carcinoma</p> </li> <li> <p>Adenocarcinoma and Its Putative Precursors and Variants</p> </li> <li> <p>Squamous Cell Carcinoma and Other Squamous Lesions</p> </li> <li> <p>Neuroendocrine Tumors</p> </li> <li> <p>Sarcomatoid Carcinoma (Carcinosarcoma)</p> </li> <li> <p>Bladder Tumors with Inverted Growth</p> </li> <li> <p>Congenital Disorders and Pediatric Neoplasms</p> </li> <li> <p>Soft Tissue Tumors</p> </li> <li> <p>Lymphoid and Hematopoietic Tumors</p> </li> <li> <p>Urothelial Carcinoma Following Augmentation Cystoplasty</p> </li> <li> <p>Other Rare Tumors</p> </li> <li> <p>Secondary Tumors</p> </li> <li> <p>Treatment Effects</p> </li> <li> <p>Handling and Reporting of Bladder Specimens</p> </li> <li> <p>Diagnostic Immunohistochemistry</p> </li> <li> <p>Pathology of the Urachus</p> </li> <li> <p>Pathology of Renal Pelvis, Ureter, and Urethra</p> </li> <li> <p>Molecular Determinants of Tumor Recurrence</p> </li> <li> <p>Urinary Cytology</p> </li> <li> <p>Evaluation of Hematuria and Urinalysis</p> </li> <li> <p>Urine-based Biomarkers</p> </li> <li> <p>Tissue-based Biomarkers</p> </li> <li> <p>Molecular Pathology of Bladder Cancer</p> </li> </ul>

SG